Clinical Utility of Highly Purified 10% Liquid Intravenous Immunoglobulin in Kawasaki Disease

Takuya Oda, Hazumu Nagata, Yasutaka Nakashima, Etsuro Nanishi, Yui Takada, Manao Nishimura, Eiji Kubo, Ken Hatae, Shouichi Ohga

Research output: Contribution to journalArticle

Abstract

Compared with a 5% intravenous immunoglobulin, a 10% intravenous immunoglobulin as the first-line treatment of Kawasaki disease significantly reduced the fever duration (10 vs 13 hours, P = .022) among the responders, and the interval to adjunctive therapy for nonresponders (47 vs 49 hours, P = .035). There were no severe adverse events.

Original languageEnglish
Pages (from-to)227-230
Number of pages4
JournalJournal of Pediatrics
Volume214
DOIs
Publication statusPublished - Nov 2019

Fingerprint

Mucocutaneous Lymph Node Syndrome
Intravenous Immunoglobulins
Fever
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health

Cite this

Clinical Utility of Highly Purified 10% Liquid Intravenous Immunoglobulin in Kawasaki Disease. / Oda, Takuya; Nagata, Hazumu; Nakashima, Yasutaka; Nanishi, Etsuro; Takada, Yui; Nishimura, Manao; Kubo, Eiji; Hatae, Ken; Ohga, Shouichi.

In: Journal of Pediatrics, Vol. 214, 11.2019, p. 227-230.

Research output: Contribution to journalArticle

Oda, Takuya ; Nagata, Hazumu ; Nakashima, Yasutaka ; Nanishi, Etsuro ; Takada, Yui ; Nishimura, Manao ; Kubo, Eiji ; Hatae, Ken ; Ohga, Shouichi. / Clinical Utility of Highly Purified 10% Liquid Intravenous Immunoglobulin in Kawasaki Disease. In: Journal of Pediatrics. 2019 ; Vol. 214. pp. 227-230.
@article{3eef03f1dbe7425aad3198f2b27b55b7,
title = "Clinical Utility of Highly Purified 10{\%} Liquid Intravenous Immunoglobulin in Kawasaki Disease",
abstract = "Compared with a 5{\%} intravenous immunoglobulin, a 10{\%} intravenous immunoglobulin as the first-line treatment of Kawasaki disease significantly reduced the fever duration (10 vs 13 hours, P = .022) among the responders, and the interval to adjunctive therapy for nonresponders (47 vs 49 hours, P = .035). There were no severe adverse events.",
author = "Takuya Oda and Hazumu Nagata and Yasutaka Nakashima and Etsuro Nanishi and Yui Takada and Manao Nishimura and Eiji Kubo and Ken Hatae and Shouichi Ohga",
year = "2019",
month = "11",
doi = "10.1016/j.jpeds.2019.06.018",
language = "English",
volume = "214",
pages = "227--230",
journal = "Journal of Pediatrics",
issn = "0022-3476",
publisher = "Mosby Inc.",

}

TY - JOUR

T1 - Clinical Utility of Highly Purified 10% Liquid Intravenous Immunoglobulin in Kawasaki Disease

AU - Oda, Takuya

AU - Nagata, Hazumu

AU - Nakashima, Yasutaka

AU - Nanishi, Etsuro

AU - Takada, Yui

AU - Nishimura, Manao

AU - Kubo, Eiji

AU - Hatae, Ken

AU - Ohga, Shouichi

PY - 2019/11

Y1 - 2019/11

N2 - Compared with a 5% intravenous immunoglobulin, a 10% intravenous immunoglobulin as the first-line treatment of Kawasaki disease significantly reduced the fever duration (10 vs 13 hours, P = .022) among the responders, and the interval to adjunctive therapy for nonresponders (47 vs 49 hours, P = .035). There were no severe adverse events.

AB - Compared with a 5% intravenous immunoglobulin, a 10% intravenous immunoglobulin as the first-line treatment of Kawasaki disease significantly reduced the fever duration (10 vs 13 hours, P = .022) among the responders, and the interval to adjunctive therapy for nonresponders (47 vs 49 hours, P = .035). There were no severe adverse events.

UR - http://www.scopus.com/inward/record.url?scp=85069696876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069696876&partnerID=8YFLogxK

U2 - 10.1016/j.jpeds.2019.06.018

DO - 10.1016/j.jpeds.2019.06.018

M3 - Article

AN - SCOPUS:85069696876

VL - 214

SP - 227

EP - 230

JO - Journal of Pediatrics

JF - Journal of Pediatrics

SN - 0022-3476

ER -